BCL11B and cancer: These findings not only enhance our understanding of the immunosuppressive mechanisms driven by epithelial-derived cancer/testis antigens but also suggest that MAGEA3, MAGEA6, BCL11B, and PAEP may serve as potential biomarkers or therapeutic targets for improving immunotherapy responses in STAD patients.